glp-1 drug novo nordisk The FDA has approved the first pill version of drugs. says participants who took the Wegovy pill in clinical trials lost an average of 16.6% of their body weight Blockbuster GLP-1 Diabetes and Weight

Wark et al

Obesity For weight loss, healthcare professionals may prescribe GLP-1 agonists for people with an initial BMI of 30 or higher or people who have a BMI of 27 or higher and at least one weight-related health condition, such as: type 2 diabetes prediabetes high blood pressure high cholesterol heart disease nonalcoholic fatty liver disease obstructive sleep apnea polycystic ovary syndrome Typically, healthcare professionals only prescribe these medications after someone has tried other weight loss methods, such as diet and exercise, without success

Where should pharma brands advertise for better results

We stock a range of sizes to suit different requirements, including: 30ml multi-dose vials available individually or in 2-packs